CIDEB and metabolic dysfunction-associated steatotic liver disease: Although whole-body Cideb deletion in mice appears to be beneficial, it is unclear if and how CIDEB somatic mutant clones are selected for within fatty livers, and if liver-specific loss of CIDEB would also protect against established MASLD.